Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

• Janaki Amin ,

  * E-mail: jamin@kirby.unsw.edu.au

  Affiliation The Kirby Institute, UNSW Australia, Sydney, Australia

  ⨯
• Mark A. Boyd,

  Affiliation The Kirby Institute, UNSW Australia, Sydney, Australia

  ⨯
• Nagalingeswaran Kumarasamy,

  Affiliation Y. R. Gaitonde Centre for AIDS Research and Education, Chennai, India

  ⨯
• Cecilia L. Moore,

  Affiliation The Kirby Institute, UNSW Australia, Sydney, Australia

  ⨯
• Marcello H. Losso,

  Affiliation Hospital JM Ramos Mejia, Buenos Aires, Argentina

  ⨯
• Chidi A. Nwizu,

  Affiliation Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States of America

  ⨯
• Lerato Mohapi,

  Affiliation University of the Witwatersrand and Baragwanath Hospital, Johannesburg, South Africa

  ⨯
• Stephen J. Kerr,

  Affiliation UNSW Australia, The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand

  ⨯
• Annette H. Sohn,

  Affiliation TREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok, Thailand

  ⨯
• Hedy Teppler,

  Affiliation Merck Research Laboratories, Merck Sharp & Dohme, Whitehouse Station, New Jersey, United States of America

  ⨯
• Boris Renjifo,

  Affiliation Global Medical Affairs Virology, Abbvie, North Chicago, Illinois, United States of America

  ⨯
• Jean-Michel Molina,

  Affiliation Service des Maladies Infectieuses, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France

  ⨯
• Sean Emery,

  Affiliation The Kirby Institute, UNSW Australia, Sydney, Australia

  ⨯
• David A. Cooper

  Affiliation The Kirby Institute, UNSW Australia, Sydney, Australia

  ⨯